Aspirin that was previously known as pain killer later used as a diluter of coagulated arteries is now can be used in treating dementia and other neuro-cardio-vascular diseases, according to Monash University, Australia. The university is fighting hard to investigate anti-dementia powers of aspirin and probably will prove it by 2018.
Dementia , a disease that affects cognitive mind is usually found among elder people resulting in memory loss and reduced retaining power. Since last five decades, it has been challenging for doctors to find a proper medication that can cure the disease. However researchers from Monash University in partnership with Berman Center for Outcomes and Clinical Research in Minneapolis, US has started trials on more than 19,000 people under ASPREE (Aspirin in Reducing Events in the Elderly) program with a budget of whopping 50 million Australian dollar.
Under ASPREE, researchers will examine properties of aspirin including its effect on neurocognitive functions, reduction in heart attack and stroke risk, etc. However, aspirin has some adverse effects too such as bleeding. Doctors will test aspirin rigorously for its adverse effects so that they can make sure that their prescription will be helpful in prolonging health.
Principal Investigator for ASPREE, Prof. John McNeil, from the Monash Department of Epidemiology and Preventive Medicine, said, “The ASPREE study is a world first as it focuses entirely on the health of our older population – those who are 70 and over. ASPREE investigators recognize that aspirin has wide-ranging potential health benefits but also that it has side effects, such as increased bleeding, which may offset its benefits. The ASPREE study will determine once and for all if the benefits of aspirin outweigh the risks.”
ASPREE involves 19,000 volunteers including 16,000 from Australia and 3,000 from USA. The program is mostly funded by the US National Institute on Aging, with funding support also received from the Australian National Health and Medical Research Council (NHMRC) and the Victorian Cancer Agency (VCA).
We can expect the results by 2018.